XtalPi Advances Cancer Treatment with Clinical Trial Approval for PRMT5 Inhibitor PEP08 XtalPi Inc. celebrates a major milestone as its PRMT5 inhibitor PEP08 receives regulatory clearance for Phase 1 clinical trials. This advancement marks a significant step in AI-driven drug discovery.

XtalPi Advances Cancer Treatment with Clinical Trial Approval for PRMT5 Inhibitor PEP08 #China #Shenzhen #XtalPi #PEP08 #PharmaEngine